Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.

A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast ...

Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

CARE Pharmacies appointed Ryan Hollingsworth, Natalie Ryan and Steven Pieri to its 2025 board of directors, and Lionel ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...

Global Alzheimer's Disease Therapeutics Market Size is expected to be worth around USD 30.8 Billion by 2033 from USD 5.5 Billion in 2023.

Daiichi Sankyo establishes “Smart” Research Laboratory in San Diego to expedite drug discovery: Tokyo Thursday, January 23, 2025, 13:00 Hrs [IST] Daiichi Sankyo, an innovative ...